For years, hardware drove innovation in laboratory instrumentation. Faster pumps, more precise liquid handling, higher-resolution detection, better automation, higher throughput: these were the specs that decided how labs judged new technology.
They still matter. But they are no longer the only things that decide whether an instrument gets adopted by the end users.
Even the best hardware can fall short if its software cannot exchange data, connect to the systems around it, or fit the way a modern lab actually works. Labs now expect an instrument to slot into a wider digital environment, whether that means talking to a LIMS, an ELN, a data analysis platform, a quality system, or other lab and enterprise applications.
So software is no longer a side component of lab equipment. In many organizations, data accessibility, integration, auditability, cybersecurity, and ease of validation weigh on a purchasing decision as heavily as the instrument’s performance.
Most of the industry’s attention goes to web and cloud-connected solutions, but desktop applications still do real work in many labs. In my experience overseeing software development at BioSistemika, the picture is more nuanced than the trend reports suggest.
The market is clearly moving toward more connected, data-centric ecosystems. That is an expansion of the options available, not a straight swap of one model for another. Plenty of labs have practical reasons to favor local applications: proximity to the instrument, heavy data processing, validated workflows, offline operation, or procedures they have already locked in.
The question is not whether software is desktop, web, or hybrid. It is whether the architecture you choose fits the instrument’s intended use, the customer’s workflow, and the regulatory environment it will run in.
Connectivity brings opportunity and new responsibilities
Connected architectures bring real advantages to the lab. Centralized data, multi-user collaboration, remote access, integration with enterprise systems, and smoother data processing can lift efficiency across the whole operation.
For HPLC, FPLC, SMB chromatography, mass spectrometry, sequencing platforms, and automated lab systems, that connectivity is becoming more valuable every year.
There is a common assumption that audit trails, data integrity, and access controls get harder to manage once systems are connected. In practice, the opposite is often true: centralizing data can make those controls easier to implement and maintain.
The complications start when systems extend beyond a closed internal environment. Remote access, API integrations, and distributed cloud infrastructure change what your security must account for. Now teams have to weigh those technical realities against regulatory and standards requirements, such as IEC 81001-5-1 for health software security and the EU Cyber Resilience Act for connected devices.
Security stops being optional. Authentication, encryption, solid access logging, vulnerability management, and a plan for long-term maintenance all belong in the architecture from the start.
The organizations that balance usability, connectivity, compliance, and security come out ahead. The ones that tackle each in isolation tend to find that fixing one thing breaks another.
Source: Unsplash
The convergence of research, pharma, and diagnostics
Many instruments start life in research and later turn up in GMP-regulated manufacturing, QC labs, or diagnostic workflows. Sometimes the customer drives that move as a new commercial opportunity opens up. That shift is a challenge for software teams.
Pharmaceutical applications demand adherence to GMP workflows, including the electronic record and signature controls set out in FDA 21 CFR Part 11 or EU GMP Annex 11. Diagnostic software, meanwhile, must align with EU IVDR requirements. Meeting those relies on established standards: IEC 62304 for the software lifecycle, ISO 14971 for risk management, and the usability engineering process defined by IEC 62366-1.
From an engineering standpoint, you can no longer design software only for today’s requirements. It has to leave enough room to support the opportunities that come later.
The point is not to predict every future regulation. It is to avoid the software architectural decisions that make adapting later far harder than it needs to be.
The ripple effect of regulatory requirements
People often assume a GMP, 21 CFR Part 11, or IVDR readiness project touches only a small corner of the application.
It rarely stays contained.
In a modern lab, software usually sits at the intersection of instrument control, method development, data processing, reporting, quality management, and system administration. A request that sounds simple, like adding electronic signatures or extending audit trails, can ripple through the whole application.
We’ve seen projects where a seemingly straightforward request turned out to depend on the database, user management, reporting modules, workflow engines, and validation processes all at once.
This does not mean the software was built badly. Usually it was built for a different purpose, at an earlier stage of the product’s life. The lesson is that flexibility matters more and more as a product moves into regulated territory.
Source: Pexels
Compliance can accelerate adoption
Over my career I’ve watched a lot of engineering teams treat compliance as an end-of-project task. A necessary, mostly paperwork step before commercialization. The trouble is that by the time compliance moves up the priority list, the architectural decisions that drive validation effort, auditability, data integrity, and long-term maintainability are already made.
This shows up most clearly when a team starts preparing software for a GMP environment, for FDA 21 CFR Part 11, or for a future diagnostic use. What looked like a documentation exercise turns out to demand real technical work on audit trails, electronic signatures, access controls, traceability, and validation support.
A growing number of teams work the other way around. Instead of leaving compliance until the end, they look at regulatory requirements early and fold them into architectural decisions as they go.
The payoff goes well past regulatory sign-off. Pharmaceutical manufacturers, hospitals, diagnostic labs, and other regulated buyers pour serious resources into qualification, validation, and risk management, usually under a quality management system aligned with ISO 13485. When your software already supports the controls and documentation they need, adoption gets much easier.
The same holds for companies eyeing future diagnostic applications. IVDR readiness takes far more than software, but an architecture built for traceability and a documented lifecycle (IEC 62304), risk management (ISO 14971), and validation from day one gives you a much stronger base to build on.
For instrument manufacturers, regulatory readiness does more than tick a box. It cuts validation effort, shortens deployment timelines, and lowers implementation risk, and it makes the product easier for customers to trust and buy.
Building software for global markets
As instrument manufacturers move into new countries, the software requirements pile up.
Different markets can bring different regulatory expectations, validation approaches, cybersecurity rules, languages, deployment models, and customer workflows. Running a separate platform for each region gets hard to sustain fast.
The better path is a flexible foundation that can absorb regional differences without splintering the product into many versions. That does not mean solving every possible future requirement now. It means making architectural choices that keep your options open and spare you costly rebuilds later. Teams that face these questions early tend to see lower lifecycle costs and move faster when they enter a new market.
The cost of waiting
Many manufacturers figure they can deal with regulatory requirements whenever a specific customer asks. In practice, it is rarely that clean.
Software platforms grow over years. Choices that make sense in research, like simplified user management, light auditability, or direct database access, can turn into real obstacles once stronger regulatory controls arrive. Again, this is not bad design. In most cases, the system was built for a different job.
We’ve seen projects where adding audit trails, electronic signatures, role-based permissions, validation support, and traceability meant changes across several layers of the architecture. What started as a small compliance task became a broad modernization effort.
Teams that assess their software architecture early usually keep more flexibility, carry less implementation risk, and have more options than teams that wait for a customer requirement or a market opening to force their hand.
Strategic timing matters
For manufacturers weighing a future pharmaceutical or diagnostic use, regulatory readiness is not a switch you flip when the moment comes. It builds up through architectural decisions made over time. The sooner a team reviews its architecture, spots the limits, and understands what regulators will expect, the more room it keeps for later.
Teams that start early are usually in a better spot to enter new markets, support new uses, and answer customer requirements without a disruptive rebuild. In a field where hardware tends to get the attention, software architecture often decides how fast those advances reach regulated markets.
Is your software architecture, whether desktop, web, or hybrid, ready to support regulated diagnostic markets?
Use our accompanying “IVD Readiness Checklist for Connected Laboratory Software” to evaluate your current platform, or contact BioSistemika for a tailored Regulatory Gap Analysis session to map out your project roadmap.
